Surface-functionalised polymeric nanoparticles for breast cancer treatment: processes and advances

References

• World Health Organization. Global breast cancer initiative implementation framework: assessing, strengthening and scaling up of services for the early detection and management of breast cancer: executive summary; 2023 [Internet]. Available from: https://www.who.int/publications/i/item/9789240067134
   Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi: 10.3322/caac.21708.
   PubMed Web of Science ®Google Scholar
• Willson ML, Burke L, Ferguson T, et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 2019;9(9):CD004421. doi: 10.1002/14651858.CD004421.pub3.
   PubMedGoogle Scholar
• Shah AN, Gradishar WJ. Adjuvant anthracyclines in breast cancer: what is their role? Oncologist. 2018;23(10):1153–1161. doi: 10.1634/theoncologist.2017-0672.
   PubMed Web of Science ®Google Scholar
• Stras S, Howe A, Prasad A, et al. Growth of metastatic triple-negative breast cancer is inhibited by deep tumor-penetrating and slow tumor-clearing chemotherapy: the case of tumor-adhering liposomes with interstitial drug release. Mol Pharm. 2020;17(1):118–131. doi: 10.1021/acs.molpharmaceut.9b00812.
   PubMedGoogle Scholar
• Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther. 2011;11(2):263–275. doi: 10.1586/era.10.226.
   PubMed Web of Science ®Google Scholar
• Xiong H, Veedu RN, Diermeier SD. Recent advances in oligonucleotide therapeutics in oncology. Int J Mol Sci. 2021;22(7):3295. doi: 10.3390/ijms22073295.
   PubMed Web of Science ®Google Scholar
• Prasad A, Nair R, Bhatavdekar O, et al. Transport-driven engineering of liposomes for delivery of α-particle radiotherapy to solid tumors: effect on inhibition of tumor progression and onset delay of spontaneous metastases. Eur J Nucl Med Mol Imaging. 2021;48(13):4246–4258. doi: 10.1007/s00259-021-05406-z.
   PubMed Web of Science ®Google Scholar
• Abu Samaan TM, Samec M, Liskova A, et al. Paclitaxel’s mechanistic and clinical effects on breast cancer. Biomolecules. 2019;9(12):789. doi: 10.3390/biom9120789.
   PubMed Web of Science ®Google Scholar
• Bernabeu E, Gonzalez L, Legaspi MJ, et al. Paclitaxel-loaded TPGS-b-PCL nanoparticles: in vitro cytotoxicity and cellular uptake in MCF-7 and MDA-MB-231 cells versus mPEG-b-PCL nanoparticles and Abraxane®. J Nanosci Nanotechnol. 2016;16(1):160–170. doi: 10.1166/jnn.2016.10739.
   PubMed Web of Science ®Google Scholar
• Gupta U, Sharma S, Khan I, et al. Enhanced apoptotic and anticancer potential of paclitaxel loaded biodegradable nanoparticles based on chitosan. Int J Biol Macromol. 2017;98:810–819. doi: 10.1016/j.ijbiomac.2017.02.030.
   PubMed Web of Science ®Google Scholar
• Foglietta F, Spagnoli GC, Muraro MG, et al. Anticancer activity of paclitaxel-loaded keratin nanoparticles in two-dimensional and perfused three-dimensional breast cancer models. Int J Nanomedicine. 2018;13:4847–4867. doi: 10.2147/IJN.S159942.
   PubMed Web of Science ®Google Scholar
• Cui Y-N, Xu Q-X, Davoodi P, et al. Enhanced intracellular delivery and controlled drug release of magnetic PLGA nanoparticles modified with transferrin. Acta Pharmacol Sin. 2017;38(6):943–953. doi: 10.1038/aps.2017.45.
   PubMed Web of Science ®Google Scholar
• Zhang X, Niu S, Williams GR, et al. Dual-responsive nanoparticles based on chitosan for enhanced breast cancer therapy. Carbohydr Polym. 2019;221:84–93. doi: 10.1016/j.carbpol.2019.05.081.
   PubMed Web of Science ®Google Scholar
• Yuan H, Guo H, Luan X, et al. Albumin nanoparticle of paclitaxel (Abraxane) decreases while taxol increases breast cancer stem cells in treatment of triple negative breast cancer. Mol Pharm. 2020;17(7):2275–2286. doi: 10.1021/acs.molpharmaceut.9b01221.
   PubMedGoogle Scholar
• Cheng Y, Wang C, Wang H, et al. Combination of an autophagy inhibitor with immunoadjuvants and an anti-PD-L1 antibody in multifunctional nanoparticles for enhanced breast cancer immunotherapy. BMC Med. 2022;20(1):411. doi: 10.1186/s12916-022-02614-8.
   PubMed Web of Science ®Google Scholar
• Sun B, Ranganathan B, Feng SS. Multifunctional poly(d,l-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by trastuzumab for targeted chemotherapy of breast cancer. Biomaterials. 2008;29(4):475–486. doi: 10.1016/j.biomaterials.2007.09.038.
   PubMed Web of Science ®Google Scholar
• Liu F, Chen Y, Li Y, et al. Folate-receptor-targeted laser-activable poly(lactide-co-glycolic acid) nanoparticles loaded with paclitaxel/indocyanine green for photoacoustic/ultrasound imaging and chemo/photothermal therapy. Int J Nanomedicine. 2018;13:5139–5158. doi: 10.2147/IJN.S167043.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Kennell C, Lee J-Y, et al. Calcium phosphate-polymer hybrid nanoparticles for enhanced triple negative breast cancer treatment via co-delivery of paclitaxel and miR-221/222 inhibitors. Nanomedicine. 2017;13(2):403–410. doi: 10.1016/j.nano.2016.07.016.
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA, Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513–2531. doi: 10.2165/00003495-200565170-00007.
   PubMed Web of Science ®Google Scholar
• Figgitt DP, Wiseman LR. Docetaxel: an update of its use in advanced breast cancer. Drugs. 2000;59(3):621–651. doi: 10.2165/00003495-200059030-00015.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zuo A, Huang X, et al. Docetaxel-loaded PAMAM-based poly(γ-benzyl-l-glutamate)-b-d-α-tocopheryl polyethylene glycol 1000 succinate nanoparticles in human breast cancer and human cervical cancer therapy. J Microencapsul. 2019;36(6):552–565. doi: 10.1080/02652048.2019.1654002.
   PubMed Web of Science ®Google Scholar
• Jain S, Spandana G, Agrawal AK, et al. Enhanced antitumor efficacy and reduced toxicity of docetaxel loaded estradiol functionalized stealth polymeric nanoparticles. Mol Pharm. 2015;12(11):3871–3884. doi: 10.1021/acs.molpharmaceut.5b00281.
   PubMed Web of Science ®Google Scholar
• Vardhan H, Mittal P, Adena SKR, et al. Long-circulating polyhydroxybutyrate-co-hydroxyvalerate nanoparticles for tumor targeted docetaxel delivery: formulation, optimization and in vitro characterization. Eur J Pharm Sci. 2017;99:85–94. doi: 10.1016/j.ejps.2016.12.007.
   PubMed Web of Science ®Google Scholar
• Abou-El-Naga AM, Mutawa G, El-Sherbiny IM, et al. Activation of polymeric nanoparticle intracellular targeting overcomes chemodrug resistance in human primary patient breast cancer cells. Int J Nanomedicine. 2018;13:8153–8164. doi: 10.2147/IJN.S182184.
   PubMed Web of Science ®Google Scholar
• Bowerman CJ, Byrne JD, Chu KS, et al. Docetaxel-loaded PLGA nanoparticles improve efficacy in taxane-resistant triple-negative breast cancer. Nano Lett. 2017;17(1):242–248. doi: 10.1021/acs.nanolett.6b03971.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li K, Liu B, et al. A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery. Biomaterials. 2010;31(35):9145–9155. doi: 10.1016/j.biomaterials.2010.08.053.
   PubMed Web of Science ®Google Scholar
• Conte C, Moret F, Esposito D, et al. Biodegradable nanoparticles exposing a short anti-FLT1 peptide as antiangiogenic platform to complement docetaxel anticancer activity. Mater Sci Eng C Mater Biol Appl. 2019;102:876–886. doi: 10.1016/j.msec.2019.04.054.
   PubMed Web of Science ®Google Scholar
• Kong N, Deng M, Sun X-N, et al. Polydopamine-functionalized CA–(PCL-ran-PLA) nanoparticles for target delivery of docetaxel and chemo-photothermal therapy of breast cancer. Front Pharmacol. 2018;9:125. doi: 10.3389/fphar.2018.00125.
   PubMed Web of Science ®Google Scholar
• Conte C, Longobardi G, Barbieri A, et al. Non-covalent strategies to functionalize polymeric nanoparticles with NGR peptides for targeting breast cancer. Int J Pharm. 2023;641:123045. doi: 10.1016/j.ijpharm.2023.122618.
   PubMedGoogle Scholar
• Nicoletto RE, Ofner CM3rd. Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells. Cancer Chemother Pharmacol. 2022;89(3):285–311. doi: 10.1007/s00280-022-04400-y.
   PubMed Web of Science ®Google Scholar
• Banu H, Sethi DK, Edgar A, et al. Doxorubicin loaded polymeric gold nanoparticles targeted to human folate receptor upon laser photothermal therapy potentiates chemotherapy in breast cancer cell lines. J Photochem Photobiol B. 2015;149:116–128. doi: 10.1016/j.jphotobiol.2015.05.008.
   PubMed Web of Science ®Google Scholar
• Yildiz T, Gu R, Zauscher S, et al. Doxorubicin-loaded protease-activated near-infrared fluorescent polymeric nanoparticles for imaging and therapy of cancer. Int J Nanomedicine. 2018;13:6961–6986. doi: 10.2147/IJN.S174068.
   PubMed Web of Science ®Google Scholar
• Hu C, Fan F, Qin Y, et al. Redox-sensitive folate-conjugated polymeric nanoparticles for combined chemotherapy and photothermal therapy against breast cancer. J Biomed Nanotechnol. 2018;14(12):2018–2030. doi: 10.1166/jbn.2018.2647.
   PubMed Web of Science ®Google Scholar
• Zhang S, Guo N, Wan G, et al. pH and redox dual-responsive nanoparticles based on disulfide-containing poly(β-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer. J Nanobiotechnol. 2019;17(1):109. doi: 10.1186/s12951-019-0540-9.
   PubMed Web of Science ®Google Scholar
• Barenholz Y. Doxil® – the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117–134. doi: 10.1016/j.jconrel.2012.03.020.
   PubMed Web of Science ®Google Scholar
• Siddharth S, Nayak A, Nayak D, et al. Chitosan-Dextran sulfate coated doxorubicin loaded PLGA–PVA-nanoparticles caused apoptosis in doxorubicin resistance breast cancer cells through induction of DNA damage. Sci Rep. 2017;7(1):2143. doi: 10.1038/s41598-017-02134-z.
   PubMedGoogle Scholar
• Mondal L, Mukherjee B, Das K, et al. CD-340 functionalized doxorubicin-loaded nanoparticle induces apoptosis and reduces tumor volume along with drug-related cardiotoxicity in mice. Int J Nanomedicine. 2019;14:8073–8094. doi: 10.2147/IJN.S220740.
   PubMed Web of Science ®Google Scholar
• Yang H, Deng L, Li T, et al. Multifunctional PLGA nanobubbles as theranostic agents: combining doxorubicin and P-gp siRNA co-delivery into human breast cancer cells and ultrasound cellular imaging. J Biomed Nanotechnol. 2015;11(12):2124–2136. doi: 10.1166/jbn.2015.2168.
   PubMed Web of Science ®Google Scholar
• Hu D, Mezghrani O, Zhang L, et al. GE11 peptide modified and reduction-responsive hyaluronic acid-based nanoparticles induced higher efficacy of doxorubicin for breast carcinoma therapy. Int J Nanomedicine. 2016;11:5125–5147. doi: 10.2147/IJN.S113469.
   PubMed Web of Science ®Google Scholar
• Maheshwari N, Kumar Atneriya U, Tekade M, et al. Guiding factors and surface modification strategies for biomaterials in pharmaceutical product development. In: Tekade RKBT-BB, editor. Biomaterials and bionanotechnology [Internet]. Elsevier; 2019. p. 57–87. Available from: https://www.sciencedirect.com/science/article/pii/B9780128144275000032
   Google Scholar
• Sur S, Rathore A, Dave V, et al. Recent developments in functionalized polymer nanoparticles for efficient drug delivery system. Nano Struct Nano Obj. 2019;20:100397. doi: 10.1016/j.nanoso.2019.100397.
   Google Scholar
• Wong KH, Lu A, Chen X, et al. Natural ingredient-based polymeric nanoparticles for cancer treatment. Molecules. 2020;25(16):3620. doi: 10.3390/molecules25163620.
   PubMed Web of Science ®Google Scholar
• Joshi MD, Patravale V, Prabhu R. Polymeric nanoparticles for targeted treatment in oncology: current insights. Int J Nanomedicine. 2015;10:1001.
   PubMed Web of Science ®Google Scholar
• Hosseini SM, Mohammadnejad J, Salamat S, et al. Theranostic polymeric nanoparticles as a new approach in cancer therapy and diagnosis: a review. Mater Today Chem. 2023;29:101400. doi: 10.1016/j.mtchem.2023.101400.
   Web of Science ®Google Scholar
• Karim S, Akhter MH, Burzangi AS, et al. Phytosterol-loaded surface-tailored bioactive-polymer nanoparticles for cancer treatment: optimization, in vitro cell viability, antioxidant activity, and stability studies. Gels. 2022;8(4):219. doi: 10.3390/gels8040219.
   PubMed Web of Science ®Google Scholar
• Ahmad MZ,Rizwanullah M,Ahmad J, et al. Progress in nanomedicine-based drug delivery in designing of chitosan nanoparticles for cancer therapy. Int J Polym Mater Polym Biomater. 2022;71(8):602–623. doi: 10.1080/00914037.2020.1869737.
   Web of Science ®Google Scholar
• Afzal O, Akhter MH, Ahmad I, et al. A β-sitosterol encapsulated biocompatible alginate/chitosan polymer nanocomposite for the treatment of breast cancer. Pharmaceutics. 2022;14(8):1711. doi: 10.3390/pharmaceutics14081711.
   PubMed Web of Science ®Google Scholar
• Othman N, Masarudin M, Kuen C, et al. Synthesis and optimization of chitosan nanoparticles loaded with l-ascorbic acid and thymoquinone. Nanomaterials. 2018;8(11):920. doi: 10.3390/nano8110920.
   Web of Science ®Google Scholar
• Iravani S, Varma RS. Alginate-based micro- and nanosystems for targeted cancer therapy. Mar Drugs. 2022;20(10):598. doi: 10.3390/md20100598.
   PubMed Web of Science ®Google Scholar
• Alvi M, Yaqoob A, Rehman K, et al. PLGA-based nanoparticles for the treatment of cancer: current strategies and perspectives. AAPS Open. 2022;8(1):12. doi: 10.1186/s41120-022-00060-7.
   Google Scholar
• Andima M, Costabile G, Isert L, et al. Evaluation of β-sitosterol loaded PLGA and PEG-PLA nanoparticles for effective treatment of breast cancer: preparation, physicochemical characterization, and antitumor activity. Pharmaceutics. 2018;10(4):232. doi: 10.3390/pharmaceutics10040232.
   PubMed Web of Science ®Google Scholar
• Shipunova VO, Sogomonyan AS, Zelepukin IV, et al. PLGA nanoparticles decorated with anti-HER2 affibody for targeted delivery and photoinduced cell death. Molecules. 2021;26(13):1–12. doi: 10.3390/molecules26133955.
   Web of Science ®Google Scholar
• Kovalenko VL, Komedchikova EN, Sogomonyan AS, et al. Lectin-modified magnetic nano-PLGA for photodynamic therapy in vivo. Pharmaceutics. 2022;15(1):92. doi: 10.3390/pharmaceutics15010092.
   PubMed Web of Science ®Google Scholar
• Zhao J, Feng SS. Effects of PEG tethering chain length of vitamin E TPGS with a Herceptin-functionalized nanoparticle formulation for targeted delivery of anticancer drugs. Biomaterials. 2014;35(10):3340–3347. doi: 10.1016/j.biomaterials.2014.01.003.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhang J, Wang Y, et al. Hyaluronic acid-coated PEI–PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy. Nanomedicine. 2016;12(2):411–420. doi: 10.1016/j.nano.2015.09.014.
   PubMed Web of Science ®Google Scholar
• Valcourt DM, Dang MN, Scully MA, et al. Nanoparticle-mediated co-delivery of notch-1 antibodies and ABT-737 as a potent treatment strategy for triple-negative breast cancer. ACS Nano. 2020;14(3):3378–3388. doi: 10.1021/acsnano.9b09263.
   PubMed Web of Science ®Google Scholar
• Valcourt DM, Day ES. Dual regulation of miR-34a and notch signaling in triple-negative breast cancer by antibody/miRNA nanocarriers. Mol Ther Nucleic Acids. 2020;21:290–298. doi: 10.1016/j.omtn.2020.06.003.
   PubMedGoogle Scholar
• Kapadia CH, Ioele SA, Day ES. Layer-by-layer assembled PLGA nanoparticles carrying miR-34a cargo inhibit the proliferation and cell cycle progression of triple-negative breast cancer cells. J Biomed Mater Res A. 2020;108(3):601–613. doi: 10.1002/jbm.a.36840.
   PubMed Web of Science ®Google Scholar
• Djafari J, Fernández-Lodeiro J, Santos HM, et al. Study and preparation of multifunctional poly(l-lysine)@hyaluronic acid nanopolyplexes for the effective delivery of tumor suppressive MiR-34a into triple-negative breast cancer cells. Materials. 2020;13(23):5309. doi: 10.3390/ma13235309.
   PubMed Web of Science ®Google Scholar
• Xu Y, Liu D, Hu J, et al. Hyaluronic acid-coated pH sensitive poly(β-amino ester) nanoparticles for co-delivery of embelin and TRAIL plasmid for triple negative breast cancer treatment. Int J Pharm. 2020;573:118637. doi: 10.1016/j.ijpharm.2019.118637.
   PubMedGoogle Scholar
• Wang S, Shao M, Zhong Z, et al. Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI–PLGA nanoparticles for the treatment of triple negative breast cancer. Drug Deliv. 2017;24(1):1791–1800. doi: 10.1080/10717544.2017.1406558.
   PubMed Web of Science ®Google Scholar
• Lee Y-H, Chang D-S. Fabrication, characterization, and biological evaluation of anti-HER2 indocyanine green-doxorubicin-encapsulated PEG-b-PLGA copolymeric nanoparticles for targeted photochemotherapy of breast cancer cells. Sci Rep. 2017;7(1):46688. doi: 10.1038/srep46688.
   PubMedGoogle Scholar
• Escareño N, Hassan N, Kogan MJ, et al. Microfluidics-assisted conjugation of chitosan-coated polymeric nanoparticles with antibodies: significance in drug release, uptake, and cytotoxicity in breast cancer cells. J Colloid Interface Sci. 2021;591:440–450. doi: 10.1016/j.jcis.2021.02.031.
   PubMedGoogle Scholar
• Powell D, Chandra S, Dodson K, et al. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer. Eur J Pharm Biopharm. 2017;114:108–118. doi: 10.1016/j.ejpb.2017.01.011.
   PubMed Web of Science ®Google Scholar
• Fernandes RS, Arribada RG, Silva JO, et al. In vitro and in vivo effect of pH-sensitive PLGA-TPGS-based hybrid nanoparticles loaded with doxorubicin for breast cancer therapy. Pharmaceutics. 2022;14(11):2394. doi: 10.3390/pharmaceutics14112394.
   PubMed Web of Science ®Google Scholar
• Li B, Xu H, Li Z, et al. Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies. Int J Nanomedicine. 2012;7:187–197.
   PubMed Web of Science ®Google Scholar
• Goyal R, Kapadia CH, Melamed JR, et al. Layer-by-layer assembled gold nanoshells for the intracellular delivery of miR-34a. Cell Mol Bioeng. 2018;11(5):383–396. doi: 10.1007/s12195-018-0535-x.
   PubMed Web of Science ®Google Scholar
• Cheaburu-Yilmaz CN, Karasulu HY, Yilmaz O. Chapter 13 – nanoscaled dispersed systems used in drug-delivery applications. In: Vasile C, editor. Polymeric nanomaterials in nanotherapeutics. Micro and nano technologies [Internet]. Elsevier; 2019. p. 437–468. Available from: https://www.sciencedirect.com/science/article/pii/B9780128139325000133
   Google Scholar
• Quérette T, Fleury E, Sintes-Zydowicz N. Non-isocyanate polyurethane nanoparticles prepared by nanoprecipitation. Eur Polym J. 2019;114:434–445. doi: 10.1016/j.eurpolymj.2019.03.006.
   Web of Science ®Google Scholar
• Pedroso-Santana S, Fleitas-Salazar N. Ionotropic gelation method in the synthesis of nanoparticles/microparticles for biomedical purposes. Polym Int. 2020;69(5):443–447. doi: 10.1002/pi.5970.
   Web of Science ®Google Scholar
• Fraguas-Sánchez AI, Lozza I, Torres-Suárez AI. Actively targeted nanomedicines in breast cancer: from pre-clinal investigation to clinic. Cancers. 2022;14(5):1198. doi: 10.3390/cancers14051198.
   PubMed Web of Science ®Google Scholar
• FDA. FDA grants regular approval to pertuzumab for adjuvant treatment of HER2-positive breast cancer; 2017 [Internet]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-pertuzumab-adjuvant-treatment-her2-positive-breast-cancer
   Google Scholar
• Srinivasarao M, Galliford CV, Low PS. Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat Rev Drug Discov. 2015;14(3):203–219. doi: 10.1038/nrd4519.
   PubMed Web of Science ®Google Scholar
• Partridge AH, Burstein HJ, Winer EP. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr. 2001;2001(30):135–142. doi: 10.1093/oxfordjournals.jncimonographs.a003451.
   Google Scholar
• Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release. 2001;74(1–3):47–61. doi: 10.1016/s0168-3659(01)00309-1.
   PubMed Web of Science ®Google Scholar
• Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013;65(1):71–79. doi: 10.1016/j.addr.2012.10.002.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Mochida A, Choyke PL, et al. Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer? Bioconjug Chem. 2016;27(10):2225–2238. doi: 10.1021/acs.bioconjchem.6b00437.
   PubMed Web of Science ®Google Scholar
• Wu J. The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application. J Pers Med. 2021;11(8):771. doi: 10.3390/jpm11080771.
   PubMed Web of Science ®Google Scholar
• Ejigah V, Owoseni O, Bataille-Backer P, et al. Approaches to improve macromolecule and nanoparticle accumulation in the tumor microenvironment by the enhanced permeability and retention effect. Polymers. 2022;14(13):2601. doi: 10.3390/polym14132601.
   PubMed Web of Science ®Google Scholar
• Rasool M, Malik A, Waquar S, et al. New challenges in the use of nanomedicine in cancer therapy. Bioengineered. 2022;13(1):759–773. doi: 10.1080/21655979.2021.2012907.
   PubMed Web of Science ®Google Scholar
• Habban Akhter M, Sateesh Madhav N, Ahmad J. Epidermal growth factor receptor based active targeting: a paradigm shift towards advance tumor therapy. Artif Cells Nanomed Biotechnol. 2018;46(Suppl. 2):1188–1198. doi: 10.1080/21691401.2018.1481863.
   PubMedGoogle Scholar
• Ahmad J, Ameeduzzafar , Ahmad MZ, et al. Surface-engineered cancer nanomedicine: rational design and recent progress. Curr Pharm Des. 2020;26(11):1181–1190. doi: 10.2174/1381612826666200214110645.
   PubMed Web of Science ®Google Scholar
• Akhter MH, Rizwanullah M, Ahmad J, et al. Nanocarriers in advanced drug targeting: setting novel paradigm in cancer therapeutics. Artif Cells Nanomed Biotechnol. 2018;46(5):873–884. doi: 10.1080/21691401.2017.1366333.
   PubMed Web of Science ®Google Scholar
• Bareford L, Swaan P. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev. 2007;59(8):748–758. doi: 10.1016/j.addr.2007.06.008.
   PubMed Web of Science ®Google Scholar
• Attia MF, Anton N, Wallyn J, et al. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol. 2019;71(8):1185–1198. doi: 10.1111/jphp.13098.
   PubMed Web of Science ®Google Scholar
• van Osdol W, Fujimori K, Weinstein JN. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a “binding site barrier”. Cancer Res. 1991;51(18):4776–4784.
   PubMed Web of Science ®Google Scholar
• Thurber GM, Zajic SC, Wittrup KD. Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med. 2007;48(6):995–999. doi: 10.2967/jnumed.106.037069.
   PubMed Web of Science ®Google Scholar
• Alexis F, Pridgen E, Molnar LK, et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505–515. doi: 10.1021/mp800051m.
   PubMed Web of Science ®Google Scholar
• Walkey CD, Olsen JB, Guo H, et al. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J Am Chem Soc. 2012;134(4):2139–2147. doi: 10.1021/ja2084338.
   PubMed Web of Science ®Google Scholar
• Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22(2):101–126. doi: 10.1038/s41573-022-00579-0.
   PubMed Web of Science ®Google Scholar
• Wang Z. ErbB receptors and cancer BT – ErbB receptor signaling: methods and protocols [Internet]; 2017. p. 3–35. Available from: doi: 10.1007/978-1-4939-7219-7_1.
   Google Scholar
• Schettini F, Pascual T, Conte B, et al. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2020;84:101965. doi: 10.1016/j.ctrv.2020.101965.
   PubMed Web of Science ®Google Scholar
• Behravan N, Zahedipour F, Jaafari MR, et al. Lipid-based nanoparticulate delivery systems for HER2-positive breast cancer immunotherapy. Life Sci. 2022;291:120294. doi: 10.1016/j.lfs.2021.120294.
   PubMed Web of Science ®Google Scholar
• Tokunaga E, Oki E, Nishida K, et al. Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol. 2006;11(3):199–208. doi: 10.1007/s10147-006-0575-4.
   PubMedGoogle Scholar
• Sitia L, Sevieri M, Signati L, et al. HER-2-targeted nanoparticles for breast cancer diagnosis and treatment. Cancers. 2022;14(10):2424. doi: 10.3390/cancers14102424.
   PubMed Web of Science ®Google Scholar
• Meng Y, Zheng L, Yang Y, et al. A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors. Oncogenesis. 2016;5(3):e211. doi: 10.1038/oncsis.2016.25.
   PubMedGoogle Scholar
• Miladinova D. Molecular imaging of HER2 receptor: targeting HER2 for imaging and therapy in nuclear medicine. Front Mol Biosci. 2023;10:1144817. doi: 10.3389/fmolb.2023.1144817.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Im S-A, Cardoso F, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer. JAMA Oncol. 2021;7(4):573–584. doi: 10.1001/jamaoncol.2020.7932.
   PubMed Web of Science ®Google Scholar
• Shipunova VO, Deyev SM. Artificial scaffold polypeptides as an efficient tool for the targeted delivery of nanostructures in vitro and in vivo. Acta Nat. 2022;14(1):54–72. doi: 10.32607/actanaturae.11545.
   PubMed Web of Science ®Google Scholar
• Kong X, Qi Y, Wang X, et al. Nanoparticle drug delivery systems and their applications as targeted therapies for triple negative breast cancer. Prog Mater Sci. 2023;134:101070. doi: 10.1016/j.pmatsci.2023.101070.
   Web of Science ®Google Scholar
• Dong S, Bi Y, Sun X, et al. Dual-loaded liposomes tagged with hyaluronic acid have synergistic effects in triple-negative breast cancer. Small. 2022;18(16):e2107690. doi: 10.1002/smll.202107690.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lin G, Yan Y, et al. Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells. Oncogene. 2018;37(25):3456–3470. doi: 10.1038/s41388-018-0221-4.
   PubMed Web of Science ®Google Scholar
• Zhu H, Bhaijee F, Ishaq N, et al. Correlation of Notch1, pAKT and nuclear NF-κB expression in triple negative breast cancer. Am J Cancer Res. 2013;3(2):230–239.
   PubMed Web of Science ®Google Scholar
• Liao W-S, Ho Y, Lin Y-W, et al. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite. Acta Biomater. 2019;86:395–405. doi: 10.1016/j.actbio.2019.01.025.
   PubMed Web of Science ®Google Scholar
• Hossein-Nejad-Ariani H, Althagafi E, Kaur K. Small peptide ligands for targeting EGFR in triple negative breast cancer cells. Sci Rep. 2019;9(1):2723. doi: 10.1038/s41598-019-38574-y.
   PubMedGoogle Scholar
• Carey L, Winer E, Viale G, et al. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7(12):683–692. doi: 10.1038/nrclinonc.2010.154.
   PubMed Web of Science ®Google Scholar
• Yang Y, Long Y, Wang Y, et al. Enhanced anti-tumor and anti-metastasis therapy for triple negative breast cancer by CD44 receptor-targeted hybrid self-delivery micelles. Int J Pharm. 2020;577(17):119085. doi: 10.1016/j.ijpharm.2020.119085.
   PubMedGoogle Scholar
• Yu C-H, Betrehem UM, Ali N, et al. Design strategies, surface functionalization, and environmental remediation potentialities of polymer-functionalized nanocomposites. Chemosphere. 2022;306:135656. doi: 10.1016/j.chemosphere.2022.135656.
   PubMed Web of Science ®Google Scholar
• Makvandi P, Iftekhar S, Pizzetti F, et al. Functionalization of polymers and nanomaterials for water treatment, food packaging, textile and biomedical applications: a review. Environ Chem Lett. 2021;19(1):583–611. doi: 10.1007/s10311-020-01089-4.
   Web of Science ®Google Scholar
• Ahmad F, Salem-Bekhit MM, Khan F, et al. Unique properties of surface-functionalized nanoparticles for bio-application: functionalization mechanisms and importance in application. Nanomaterials. 2022;12(8):1333.
   Web of Science ®Google Scholar
• Sanità G, Carrese B, Lamberti A. Nanoparticle surface functionalization: how to improve biocompatibility and cellular internalization. Front Mol Biosci. 2020;7:587012. doi: 10.3389/fmolb.2020.587012.
   PubMed Web of Science ®Google Scholar
• Nobs L, Buchegger F, Gurny R, et al. Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci. 2004;93(8):1980–1992. doi: 10.1002/jps.20098.
   PubMed Web of Science ®Google Scholar
• Lu J, Shi M, Shoichet MS. Click chemistry functionalized polymeric nanoparticles target corneal epithelial cells through RGD-cell surface receptors. Bioconjug Chem. 2009;20(1):87–94. doi: 10.1021/bc8003167.
   PubMed Web of Science ®Google Scholar
• Gessner I, Neundorf I. Nanoparticles modified with cell-penetrating peptides: conjugation mechanisms, physicochemical properties, and application in cancer diagnosis and therapy. Int J Mol Sci. 2020;21(7):2536. doi: 10.3390/ijms21072536.
   PubMed Web of Science ®Google Scholar
• Qian Y, Zhang J, Xu R, et al. Nanoparticles based on polymers modified with pH-sensitive molecular switch and low molecular weight heparin carrying celastrol and ferrocene for breast cancer treatment. Int J Biol Macromol. 2021;183:2215–2226. doi: 10.1016/j.ijbiomac.2021.05.204.
   PubMed Web of Science ®Google Scholar
• Yu K, Zhao J, Zhang Z, et al. Enhanced delivery of paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells. Int J Pharm. 2016;497(1–2):78–87. doi: 10.1016/j.ijpharm.2015.11.033.
   PubMed Web of Science ®Google Scholar
• Zheng D, Wan C, Yang H, et al. Her2-targeted multifunctional nano-theranostic platform mediates tumor microenvironment remodeling and immune activation for breast cancer treatment. Int J Nanomedicine. 2020;15:10007–10028. doi: 10.2147/IJN.S271213.
   PubMed Web of Science ®Google Scholar
• Elhabak M, Osman R, Mohamed M, et al. Near IR responsive targeted integrated lipid polymer nanoconstruct for enhanced magnolol cytotoxicity in breast cancer. Sci Rep. 2020;10(1):8771. doi: 10.1038/s41598-020-65521-z.
   PubMed Web of Science ®Google Scholar
• Fan Z, Fu PP, Yu H, et al. Theranostic nanomedicine for cancer detection and treatment. J Food Drug Anal. 2014;22(1):3–17. doi: 10.1016/j.jfda.2014.01.001.
   PubMed Web of Science ®Google Scholar
• Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev. 2010;62(11):1052–1063. doi: 10.1016/j.addr.2010.08.004.
   PubMed Web of Science ®Google Scholar
• Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconjug Chem. 2011;22(10):1879–1903. doi: 10.1021/bc200151q.
   PubMed Web of Science ®Google Scholar
• Cabral H, Nishiyama N, Kataoka K. Supramolecular nanodevices: from design validation to theranostic nanomedicine. Acc Chem Res. 2011;44(10):999–1008. doi: 10.1021/ar200094a.
   PubMed Web of Science ®Google Scholar